Squamous Non-Small Cell Lung Cancer Therapeutics Market: Key Drugs & Clinical Trials By 2031 | Most Leading Companies - Genentech, Bristol Myers Squibb, Eli Lilly and Company, AstraZeneca, Pfizer Inc., Novartis AG

The Global Squamous Non-Small Cell Lung Cancer Therapeutics Market reached US$4 billion in 2023 and is expected to reach US$ 8.06 billion by 2031, growing at a CAGR of 9.4% during the forecast period 2024-2031.

Squamous Non-Small Cell Lung Cancer Therapeutics Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Request a Free Sample PDF of This Report (Corporate Email IDs Receive Priority Service): https://datamintelligence.com/download-sample/squamous-non-small-cell-lung-cancer-therapeutics-market?kb

Squamous Non-Small Cell Lung Cancer (NSCLC) therapeutics focus on targeted therapies, immunotherapies, and chemotherapy treatments designed specifically for squamous cell carcinoma, a subtype of NSCLC. These treatments aim to improve survival rates, manage symptoms, and enhance quality of life in affected patients.

List of the Key Players in the Squamous Non-Small Cell Lung Cancer Therapeutics Market:

Genentech, Bristol Myers Squibb, Eli Lilly and Company, AstraZeneca, Pfizer Inc., Novartis AG, Merck Sharp & Dhome Corporation, Breckenridge Pharmaceutical Inc., Teva Pharmaceuticals Inc., Apotex Corporation among others.

Industry Development:

In January 2024, a multi-cohort phase II clinical trial (NCT05329025) conducted by Sun Yat-sen University Cancer Center evaluated the safety and efficacy of QL1706-a bifunctional MabPair antibody targeting PD-1 and CTLA-4-in combination with chemotherapy, with or without bevacizumab, in patients with advanced non-small cell lung cancer (NSCLC). The study found that QL1706 combined with chemotherapy, irrespective of bevacizumab use, was generally well tolerated and exhibited encouraging antitumor activity in EGFR wild-type NSCLC patients in a first-line setting. Notably, the addition of bevacizumab to QL1706 and chemotherapy yielded enhanced efficacy in EGFR-mutated NSCLC cases.

In February 2024, researchers at the University of Science and Technology of China highlighted that platinum-based dual-drug first-line chemotherapy remains a standard approach for advanced NSCLC but has limited effectiveness. Bevacizumab, which inhibits vascular endothelial growth factor (VEGF), disrupts tumor angiogenesis and hinders tumor growth and invasion. When used in combination with chemotherapy, bevacizumab demonstrated superior antitumor efficacy compared to chemotherapy alone.

Research Process:

Both primary and secondary data sources have been used in the global Squamous Non-Small Cell Lung Cancer Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/squamous-non-small-cell-lung-cancer-therapeutics-market?kb

Segment Covered in the Squamous Non-Small Cell Lung Cancer Therapeutics Market:

By Therapy type: Targeted Therapy, Immunotherapy, Chemotherapy, Others

By End-User: Hospitals, Specialty Clinics, Others

Regional Analysis for Squamous Non-Small Cell Lung Cancer Therapeutics Market:

The regional analysis of the Squamous Non-Small Cell Lung Cancer Therapeutics Market covers key regions including North America, Europe, Asia Pacific Middle East and Africa and South America. The North America with a focus on the U.S., Canada, and Mexico; Europe, highlighting major countries like the U.K., Germany, France, and Italy, along with other nations in the region; Asia-Pacific, covering India, China, Japan, South Korea, and Australia, among others; South America, with emphasis on Colombia, Brazil, and Argentina; and the Middle East & Africa, which includes Saudi Arabia, the U.A.E., South Africa, and other countries. This comprehensive regional breakdown helps identify unique market trends and growth opportunities specific to each area.

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/squamous-non-small-cell-lung-cancer-therapeutics-market?kb

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the Squamous Non-Small Cell Lung Cancer Therapeutics market?

➠ Who are the leading manufacturers in the global Squamous Non-Small Cell Lung Cancer Therapeutics industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global Squamous Non-Small Cell Lung Cancer Therapeutics industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the Squamous Non-Small Cell Lung Cancer Therapeutics market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.